Insulin Resistance and Accelerated Cognitive Aging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03039647|
Recruitment Status : Recruiting
First Posted : February 1, 2017
Last Update Posted : April 17, 2018
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Official Title:||Insulin Resistance and Accelerated Cognitive Aging|
|Actual Study Start Date :||January 1, 2017|
|Estimated Primary Completion Date :||January 1, 2022|
|Estimated Study Completion Date :||January 1, 2022|
Entry Point IR (SSPG, HOMA-IR)
All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
Change in IR (HOMA-IR)
The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
- Change in hippocampal connectivity [ Time Frame: Change in hippocampal connectivity from entry point to exit point three years later ]This will be assessed by MRI and cognitive assessments.
- Change in hippocampal volume [ Time Frame: Change in hippocampal volume from entry point to exit point three years later ]This will be determined by MRI analysis.
- Change in memory-related functional activation [ Time Frame: Change in memory-related functional activation from entry point to exit point three years later ]This will be determined by MRI analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039647
|Contact: Siena Roat-Shumway, B.S.||firstname.lastname@example.org|
|Contact: Alison Myoraku, B.S.||email@example.com|
|United States, California|
|Stanford Psychiatry Building||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Siena Roat-Shumway, B.S. 650-724-4559 firstname.lastname@example.org|
|Contact: Alison Myoraku, B.S. 6507362182 email@example.com|
|Principal Investigator: Natalie Rasgon, M.D., Ph.D.|
|Principal Investigator:||Natalie Rasgon, M.D., Ph.D.||Stanford University|